EHA 2023 | AML19 update: improvement in OS in patients with NPM1-mutated AML treated with FLAG-Ida-GO
Nigel Russell, MD, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, gives an update on the AML19 trial (NCT01093514) comparing FLAG-Ida plus gemtuzumab ozogamicin (GO) versus daunorubicin-araC (DA) with GO in patients with NPM1-mutated acute myeloid leukemia (AML). The trial showed a significant improvement in survival in patients treated with FLAG-Ida-GO. Additionally, patients who were measurable residual disease (MRD)-negative following two cycles of FLAG-Ida did not require further consolidation therapy. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Jazz Pharmaceuticals
